This open-label, multi-center study from Mexico compared the efficacy and safety of oral sildenafil and phentolamine in men with erectile dysfunction. Patients received sildenafil (25 -100 mg; n ¼ 123) or phentolamine (40 mg; n ¼ 119) for 8 weeks, and efficacy was assessed using the International Index of Erectile Function (IIEF) as well as two global efficacy questions. Mean scores for the erectile function domain of the IIEF were significantly higher for sildenafil (27.23 AE 0.62; P ¼ 0.0001) than for phentolamine (19.35 AE 0.66). Approximately twice as many men receiving sildenafil had successful attempts at sexual intercourse (88% vs 42%), improved erections (95% vs 51.1%), and improved ability to have sexual intercourse (94.4% vs 46.4%) compared with phentolamine. The most common adverse events included rhinitis, headache, tachycardia, and nausea, with a higher frequency reported in patients receiving phentolamine than sildenafil (41% vs 33%), with the exception of headache, which was reported more frequently in sildenafil users. Overall, sildenafil was more effective and appeared to be better tolerated than phentolamine for the treatment of erectile dysfunction.
Introduction
Sildenafil citrate (Viagra 1 ) is a potent and selective inhibitor of cGMP-dependent phosphodiesterase 5, which is the predominant phosphodiesterase of human corpus cavernosum. 1 It thus enhances relaxation of the penile corpus cavernosum induced by nitric oxide-mediated neurotransmission and improves penile erectile function. 2 Sildenafil is the first orally active therapy for erectile dysfunction (ED) of varying etiologies. 3 After more than 11 000 patient-years of observation in clinical trials, sildenafil has been shown to be effective and well tolerated in patients with a wide range of comorbidities, including diabetes, stable cardiovascular disease, treated prostate cancer, spinal cord injury, end-stage renal disease, minor depression, multiple sclerosis, and Parkinson's disease. 4 -9 Phentolamine has been used since 1984 for the intracavernosal treatment of ED. 10 It is believed to elicit smooth muscle relaxation in the corpus cavernosum by a dual mechanism of action: (1) by directly antagonizing a-adrenergic agonists at the receptor level, thereby reducing intracellular calcium release and inhibiting contractility; and (2) by indirectly enhancing nitric oxide synthase activity, thereby increasing cGMP levels and promoting relaxation. Both mechanisms contribute to its relaxing effect on corpus cavernosum erectile tissue and facilitation of erection. 11, 12 Because of inherent problems with self-injection, there has recently been renewed interest in an oral administration of phentolamine. The first demonstration of the effectiveness of oral phentolamine for the treatment of ED was in 1988, when a placebo-controlled crossover study showed that eight of 16 men responded to phentolamine 50 mg and not to placebo. 13 Since that time, another small study in which patients were initially screened for their ability to tolerate the hypotensive effects of phentolamine showed that oral doses of 20 -60 mg were effective but in less than half of the men who received the drug. 14 Although not formally reported, preliminary results of phase III clinical studies conducted in more than 3800 patients suggest improved erectile function in 53% and 63% of men taking oral phentolamine 40 mg and 80 mg, respectively, compared with 28% taking placebo. 12 At the time of this writing, oral phentolamine is approved for the treatment of ED only in Mexico and Brazil.
This study was conducted to compare the efficacy and safety of sildenafil citrate and phentolamine mesylate in men with ED of organic, psychogenic, or mixed etiology.
Materials and methods
This was an open-label, randomized, multicenter, parallel-group study conducted between 8 January 1999, and 22 June 1999, at 17 centers in Mexico in compliance with ethical committee and informed consent regulations. The study was conducted over a 12-week period and consisted of a 4-week no-treatment run-in period followed by an 8-week open-label treatment period.
Eligible patients were 18 y or older, had at least a 6-month history of ED, and were in a stable sexual relationship with a female partner. They had mild to moderate ED as determined by investigator rating of the erectile function domain of the International Index of Erectile Function (IIEF) questionnaire (questions 1 -5 and 15) (Q1 -Q5, Q15). 15 These questions assessed the ability to get an erection (Q1), the frequency of erections that were hard enough for penetration (Q2), the frequency of penetration (Q3), the frequency of maintained erection (Q4), the chance of maintaining erection until completion (Q5), and the self-confidence to get and maintain an erection (Q15). Each was scored on a scale of 1 -5, with 1 representing the worst response and 5 the best. A score between 11 and 25 was required for study entry. The investigators classified the etiology of ED as organic, psychogenic, or mixed, based on medical history and physical examination. Patients were to be otherwise healthy (determined by clinical laboratory tests and physical examination performed at screening) and free of clinically significant diseases, psychological conditions, or social circumstances that would impair their ability to participate in the study or put themselves or others at risk by participating. They were also to be free of any other factors that could interfere with the evaluation of the study results or affect patient safety. Such factors included genital anatomic deformities that impair erection, ED due to another primary sexual disorder, history of spinal cord injury or radical prostatectomy, marked liver function abnormalities, history of gastroduodenal ulceration, or known history of retinitis pigmentosa. Patients were not to have used any investigational drugs within 6 weeks of study entry and were not to be taking medications causally associated with ED unless these were prescribed more than 2 weeks before entry and dose adjustments were not anticipated during the study. Patients were required to discontinue all other therapies for ED for the duration of the study and were not to donate blood or blood products during the study and 1 month thereafter. Patients with known hypersensitivity or previous intolerance to sildenafil, phentolamine, or other components of the tablets as well as those currently taking contraindicated medications (nitrates or nitric oxide donors for sildenafil and alpha blockers for phentolamine) were ineligible for the study.
After the 4-week run-in period, during which baseline data on sexual function were collected, patients were randomized to receive sildenafil or phentolamine for 8 weeks on an outpatient basis. Patients were to take one tablet approximately 30 min (phentolamine) or 1 h (sildenafil) before anticipated sexual activity but were not to take more than one tablet daily. Patients receiving sildenafil were started at a dose of 50 mg. At the investigator's discretion, this could be increased to 100 mg if ED was not sufficiently improved, provided the 50-mg dose had been well tolerated. Dose reductions were allowed if patients experienced intolerable adverse effects. For patients receiving 50 mg, the dose could be reduced to 25 mg; for patients receiving 100 mg, the dose could be reduced to 50 mg. Patients randomized to phentolamine received a dose of 40 mg with no adjustment in dose.
Efficacy was assessed on the basis of patient responses to the IIEF questionnaire, which was administered at baseline and at the end of the 8-week treatment period (or at the time of discontinuation for subjects who discontinued early). The primary efficacy measure was the erectile function domain (Q1 -Q5, Q15) of the IIEF, rated as previously described. Other domains, including orgasmic function (frequency of ejaculation and orgasm= climax; Q9 and Q10), sexual desire (frequency of feelings and rating of sexual desire; Q11 and Q12), intercourse satisfaction (attempts at and satisfaction and enjoyment of sexual intercourse; Q6 -Q8), and overall satisfaction (with sex life and sexual relationship with partner; Q13 and Q14), and individual questions of the IIEF were also analyzed. Responses ranged from 1 (almost never=never or very low) to 5 (almost always=always or very high), with a score of 0 indicating no attempt at sexual intercourse. During the entire 12-week study period, patients also completed an event log each time they engaged in sexual activity and=or took study medication. The event log recorded whether or not study medication was taken, whether or not sexual intercourse was successful, whether the erection was hard enough or lasted long enough to complete the sexual activity, and the latency between dosing and successful sexual intercourse. At the end of the 8-week treatment period, patients also responded 'yes' or 'no' to two global efficacy assessment questions, which asked whether they experienced an improvement in the quality of their erection and in their overall sexual ability.
Safety was assessed by changes in vital signs and adverse events that occurred during treatment and up to 7 days after the last dose of study medication.
The treatment groups were checked for similarity with respect to demographic and event log variables using descriptive statistics. Intention-to-treat analyses were performed on all efficacy variables and included all patients with at least one assessment after baseline and who had taken at least one dose of study medication; safety analyses were based on all patients who took at least one dose of study medication. The primary efficacy variable (erectile function domain score) as well as other domain scores and responses to individual questions of the IIEF were analyzed using analysis of covariance, including terms for treatment, center, and baseline value of the efficacy variables. Responses to the global efficacy assessment questions and the proportion of successful intercourse events derived from the event logs were analyzed for a difference between the treatment groups using logistic regression. The Cochran-Mantel-Haenszel statistic was used to analyze differences between treatments in the latency between dosing and successful intercourse. Covariates modeled in all analyses included age, duration of disease, history of smoking, and etiology of disease. All tests of hypotheses were performed at the 5% significance level using twosided tests of significance.
Results
A total of 249 patients were screened. Of these, 242 were randomized (123 to sildenafil and 119 to phentolamine) and took at least one dose of study medication. Treatment groups were similar with regard to demographic characteristics and etiology of ED, with patients ranging in age from 25 to 80 y and duration of ED ranging from 6 months to 34 y; most patients had ED of mixed etiology (Table 1) . At the end of the study, the majority of patients (n ¼ 67) in the sildenafil group were taking the 50-mg dose; only two were taking 25 mg, and the others (n ¼ 51) were taking 100 mg. All patients in the phentolamine group received 40-mg doses throughout the study. The median number of doses taken per month were 16.0 AE 6.7 (n ¼ 123) and 10.7 AE 6.6 (n ¼ 119) for sildenafil and phentolamine, respectively.
Baseline mean scores for the erectile function domain of the IIEF were similar for patients randomized to sildenafil or phentolamine (16.26 vs 15.36, respectively). After treatment with sildenafil, the least squares mean score for this domain was 27.23 (maximum, 30), which was statistically significantly (P < 0.0001) greater than the score of 19.35 after treatment with phentolamine (Table 2) . Likewise, baseline mean scores for orgasmic function (6.57 vs 6.00), sexual desire (6.81 vs 6.78), intercourse satisfaction (8.21 vs 7.85), and overall satisfaction (4.82 vs 4.59) were similar for the two groups but were statistically significantly (P < 0.0001) higher after treatment with sildenafil than after treatment with phentolamine ( Table 2 ). Scores for each individual question of the IIEF were also statistically significantly (P < 0.0001) higher for patients receiving sildenafil, ranging between 3.89 and 4.70 (maximum, 5) compared with 2.73 and 3.98 for patients receiving phentolamine.
Data from the event log of erectile function indicated that the mean number of successful attempts at sexual intercourse per week was 3.11 in the sildenafil group. This was significantly higher than the 1.17 successful attempts per week in the phentolamine group (P ¼ 0.0001). The per cent of successful attempts at sexual intercourse is shown in Figure 1 , along with the per cent of at least one successful attempt at sexual intercourse and the per cent of men responding 'yes' to the global efficacy assessment questions, which indicated improved erections and overall sexual ability. Significantly more men receiving sildenafil than placebo had at least one successful attempt at intercourse (94.8% vs 65.2%), improved erections (95.1% vs 51.1%) and improved sexual ability (94.4% vs 46.4%; P ¼ 0.0001) (Figure 1 ). Statistically significantly lower (P < 0.0001) than sildenafil.
Comparison of the efficacy and safety of sildenafil with phentolamine E Ugarte and A Hurtado-Coll A total of 29 patients discontinued from the study, nine for reasons unrelated to the study drug. Of the 20 discontinuations related to study drug, 19 were from the phentolamine group: 15 discontinued due to lack of efficacy, three due to adverse events (dyspnea and tachycardia, epistaxis, cephalea), and one due to a serious adverse event (flushing, chest pain, shortness of breath, and tachycardia). The other treatment-related discontinuation was due to adverse events (dizziness and tachycardia) in a patient receiving sildenafil.
Overall, adverse events were experienced by 49 patients (41.2%) in the phentolamine group and 41 (33.3%) in the sildenafil group. Cardiovascular adverse events (such as palpitations and tachycardia) were observed more frequently in patients receiving phentolamine than in patients receiving sildenafil (1.7% and 5.9% vs 0% and 0.8%, respectively). Respiratory (17.6% vs 8.9%) and digestive (12.6% vs 9.8%) complaints were also more frequent in patients receiving phentolamine compared with patients receiving sildenafil. Adverse events occurring in 3% or more patients in either group are shown in Table 3 . The most common adverse events occurring during the study were headache (for patients receiving sildenafil) and rhinitis (for patients receiving phentolamine) ( Table 3) . Most adverse events (95%) were mild or moderate in nature. Besides the serious adverse event that led to discontinuation in a patient receiving phentolamine, there were three other serious adverse events, none of which were considered related to study drug; two were in patients receiving phentolamine (cerebrovascular accident, worsening of existing pterygium) and one in a patient receiving sildenafil (ruptured Achilles tendon). There were no significant changes in vital signs during the study.
Discussion
This study was designed to reflect clinical practice, with patients taking study medication according to the instructions in the respective package inserts for the drugs. Those randomized to sildenafil were started at a dose of 50 mg with allowance for increases (to 100 mg) or decreases (to 25 mg) in dose depending on efficacy and tolerability. Those randomized to phentolamine were given a fixed dose of 40 mg. Both drugs were given as required for 8 weeks. Under these conditions, the overall results of this open-label, parallel-group study indicate that oral sildenafil is better tolerated and more effective than oral phentolamine in the treatment of ED in men with disease of psychogenic, organic, or mixed etiology.
The erectile function domain of the IIEF (the primary efficacy variable) was more improved by 8 weeks of treatment with sildenafil compared with phentolamine. Indeed, the erectile function score approached the maximum score of 30 after treatment with sildenafil (27.23) and was significantly higher than the score after treatment with phentolamine (19.35) (P < 0.0001). Consistent with this result, nearly twice as many men receiving sildenafil than phentolamine reported improved erections (95.1% vs 51.1%, respectively) (P ¼ 0.0001). The results with phentolamine are generally comparable with rates of improved erections reported in other studies, ranging from 20% to 63% for doses between 20 and 80 mg. 12 -14 On the other hand, rates of improved erections for sildenafil in this study were somewhat higher than those previously reported, which were generally between 65% and 88%. 16 
Table 3
Most common treatment-related adverse events with sildenafil or phentolamine Comparison of the efficacy and safety of sildenafil with phentolamine E Ugarte and A Hurtado-Coll
Reflective of the improved erections, sildenafil also improved other aspects of sexual intercourse to a greater extent than phentolamine. This included other domains as well as individual items of the IIEF. As for erectile function, other domain scores approached maximum after treatment with sildenafil. Thus, scores for intercourse satisfaction (13.69= 15) , orgasmic function (9.25=10), sexual desire (7.98=10), and overall satisfaction (8.49=10) as well as the individual items contributing to these scores were all significantly higher after treatment with sildenafil than treatment with phentolamine (P < 0.0001). Sildenafil also significantly improved the proportion of attempts at sexual intercourse that were successful. Indeed, twice as many attempts were successful after treatment with sildenafil than after treatment with phentolamine (88.3% vs 42.2%, respectively) (P ¼ 0.0001), and there were almost three times as many successes per week after treatment with sildenafil than after treatment with phentolamine (3.11 vs 1.17, respectively) (P < 0.0001). Overall, these data indicate that more patients receiving sildenafil than phentolamine who attempted sexual intercourse were successful. Again, these results were reflected in the patients' overall rating of sexual ability. More than twice as many patients receiving sildenafil than phentolamine reported that the study medication had improved their sexual ability (94.4% vs 46.4%, respectively) (P ¼ 0.0001).
More patients receiving sildenafil than phentolamine had at least one successful attempt at sexual intercourse (95% vs 65.2%, respectively).
Overall, patients receiving sildenafil had improved erections that resulted in more frequent successful sexual intercourse than patients receiving phentolamine. This is reflected by the fact that 12.6% of patients in the phentolamine group discontinued because of lack of efficacy. By contrast, none of the patients receiving sildenafil discontinued for this reason.
The overall incidence of treatment-related adverse events was lower for sildenafil than for phentolamine (33.3% vs 41.2%, respectively). Only one patient in the sildenafil group discontinued due to treatment-related adverse events compared with four in the phentolamine group, one of whom had a serious adverse event. Sildenafil was well tolerated, with mild headache the most frequently reported adverse event in this group of patients, occurring at a frequency of 11.4%. Flushing was the only other adverse event that occurred more frequently in patients taking sildenafil, and this occurred at a frequency of < 5%. Both of these are well-recognized adverse effects of sildenafil and are the most common adverse effects seen in placebo-controlled clinical trials of sildenafil. 4 The overall frequency of cardiovascular adverse events as well as respiratory and digestive adverse events was higher in patients receiving phentolamine. Rhinitis, with a frequency of 12.6%, was the most common adverse event observed in patients receiving phentolamine; this was also reported most frequently in other trials. 12 Headache, tachycardia, and nausea also occurred at a frequency of 5% or more in patients receiving phentolamine. Overall, sildenafil appeared to be better tolerated than phentolamine in this study population.
Conclusions
The treatment of ED is moving out of the arena of specialist care as alternatives to invasive therapies become available and more men request oral medications for treatment of this disorder. The results of this study provide important information for clinicians managing patients with ED. In a population in which both sildenafil and phentolamine are available as oral medications, more patients experience improvements in erectile function and intercourse satisfaction with sildenafil. The overall results of this study indicate that oral sildenafil is better tolerated than oral phentolamine in men, and its efficacy in the treatment of ED is also superior in this population.
